Modifiable Risk Factors Propel Anti-Asthmatics And COPD Drug Market: Transformative Forces Shaping the Anti-Asthmatics And COPD Drugs Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Anti-Asthmatics And COPD Drugs Industry Market Size Be by 2025?
The market for anti-asthmatic and COPD medications has seen a robust growth in recent years. The market size is predicted to rise from $80.85 billion in 2024 to $85.08 billion in 2025, exhibiting a compounded annual growth rate (CAGR) of 5.2%. The historical growth in this market can be linked to factors such as the growing incidence of respiratory diseases, rising tobacco smoking, the effects of global warming, the aging population, the emergence of new markets, advancements in drug discovery strategies, and increasing healthcare expenditures.

What's the Long-Term Growth Forecast for the Anti-Asthmatics And COPD Drugs Market Size Through 2029?
The market for anti-asthmatics and COPD drugs is forecasted to experience significant expansion in the next few years, reaching a value of $105.07 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 5.4%. This anticipated growth in the coming years is primarily driven by factors such as the growing use of e-cigarettes or vaping, escalating obesity rates, advancements in technology, a sizeable undiagnosed population, utilization of anti-asthmatics and COPD drugs for treating COVID-19, and the growing intake of fats. The future market trends include the creation of probiotic drugs for asthma, advancing anti-IL-5 drugs to broaden their business scope, launching innovative products to reinforce and maintain market presence amid fierce competition, investing more in the development of bioelectric medicines, focusing on enhancing collaborative efforts, offering personalized treatments, and the creation of combination drugs for improved effectiveness. The market also anticipates the development of biologics responding to its increasing demand.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Anti-Asthmatics And COPD Drugs Market Expansion?
Adjustable risk elements like smoking, absence of physical activity, and improper eating patterns contribute to the progression of the anti-asthmatics and COPD drugs market. Despite a global decline in smoking incidence, it's on the rise in developing countries like China, India, Indonesia, and Nigeria. For instance, tobacco smoking is predicted to rise by 24 million in Indonesia and by 7 million in Nigeria by 2025, and China accounts for more than 40% of the global cigarette usage. The intake of fats, including saturated fatty acids, which exacerbates Asthma and COPD, is higher in wealthy countries like the USA and Europe. As per WHO, in developed nations, fats supply more than 35% of total energy needs, compared to less than 20% in low-income countries, and less than 25% in lower-middle-income countries.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

What Trends Will Shape the Anti-Asthmatics And COPD Drugs Market Through 2029 and Beyond?
Top firms in the anti-asthmatics and COPD drugs market are driving profitability through innovation, such as the combination drug Indacaterol plus Mometasone. This drug, administered through the Breezhaler device, is a once-daily fixed-dose combination (FDC) tailored for long-term asthma management. For instance, Glenmark Pharmaceuticals, an American pharma company, introduced a breakthrough fixed-dose combo (FDC) medication, Indacaterol plus Mometasone, in June 2022 to treat patients with uncontrollable asthma in India. This drug, sold under the brand name Indamet, is available in three different versions, all of which include a standard dose of 150 mcg Indacaterol and varying amounts of Mometasone, in 80 mcg, 160 mcg, and 320 mcg strengths.

How Is the Anti-Asthmatics And COPD Drugs Market Segmented?
The anti-asthmatics and copd drugs market covered in this report is segmented -

1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60

Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp

Which Companies Are Leading the Charge in Anti-Asthmatics And COPD Drugs Market Innovation?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria

Which Regions Are Leading the Global Anti-Asthmatics And COPD Drugs Market in Revenue?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3802

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.